EPI M13Alternative Names: EPI-M13
Latest Information Update: 07 Jan 2016
At a glance
- Originator EpiPharm AG
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Melanosis
Most Recent Events
- 07 Jan 2016 EpiPharm plans a phase I/II trial for Melanosis
- 07 Jan 2016 Preclinical development for Melanosis is ongoing in Switzerland
- 01 Jan 2014 Preclinical trials in Melanosis in Switzerland (Topical)